Syngle Therapeutics

Executive Summary

Syngle Therapeutics is a Dutch biotechnology company founded in 2021, based in Leiden, developing a disease-modifying immunotherapy for Parkinson's disease. Its innovative approach uses proprietary antibodies that specifically target toxic oligomeric forms of alpha-synuclein, a key pathological protein in Parkinson's. Uniquely, the company employs a gene therapy delivery method to enable sustained, local antibody production in the brain following a single administration. This combination of antibody specificity and durable expression could address a critical unmet need by potentially slowing or halting disease progression, unlike current symptomatic treatments. Currently in the pre-clinical stage, Syngle is advancing toward IND-enabling studies. The company's technology has the potential to be first-in-class, but it faces typical early-stage risks, including manufacturing challenges for gene therapy vectors and immunological complications. Success would depend on demonstrating safety and efficacy in animal models and subsequently in human trials. The company has not disclosed funding details, but its focused pipeline and experienced leadership in Leiden's biotech hub position it well for investor interest as it approaches key milestones.

Upcoming Catalysts (preview)

• H1 2027IND filing for lead candidate40% success
• H2 2026Series A financing round60% success
• Q3 2026Publication of preclinical efficacy data70% success